[April 29, 2016]

Keratoconjunctivitis sicca (Dry Eye) Pipeline Review, H1 2016 - Research and Markets

Research and Markets has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Keratoconjunctivitis sicca (Dry Eye) Overview
3. Therapeutics Development
4. Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview
5. Pipeline Products for Keratocojunctivitis sicca (Dry Eye) - Comparative Analysis
6. Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies
7. Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes
8. Keratoconjunctivitis sicca (Dry Eye) Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies
13. Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes
14. Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development

• AB2 Bio Ltd.
• Akari Therapeutics, Plc
• Allergan Plc
• Circadian Technologies Limited
• Delenex Therapeutics AG
• Digna Biotech, S.L.
• Dompe Farmaceutici S.p.A.
• HanAll Biopharma Co., Ltd.
• Herantis Pharma Plc
• Huons Co., Ltd.
• InSite Vision Incorporated
• Kala Pharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Kukje Pharmaceutical Industry Co., Ltd.
• Laboratorios Sophia S.A. de C.V.
• Lee's Pharmaceutical Holdings Limited
• Lipicard Technologies Limited
• Merck & Co., Inc.
• Mimetogen Pharmaceuticals Inc.
• Mitotech S.A.
• Nanomerics Ltd
• Neuroptis Biotech
• Novaliq GmbH
• Ocular Therapeutix, Inc.
• Oculis ehf
• OncoNOx ApS
• Otsuka Holdings Co., Ltd.
• Parion Sciences, Inc.
• PharmaReaserch Products Co., Ltd.
• RegeneRx Biopharmaceuticals, Inc.
• Rigel Pharmaceuticals, Inc.
• Shire Plc
• Sucampo Pharmaceuticals, Inc.
• TearSolutions, LLC.
• Xigen SA

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005510/en/

[ Back To TMCnet.com's Homepage ]